American Century Companies Inc. Has $6.65 Million Stock Position in Health Catalyst, Inc. (NASDAQ:HCAT)

American Century Companies Inc. grew its stake in shares of Health Catalyst, Inc. (NASDAQ:HCATFree Report) by 10.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 657,552 shares of the company’s stock after buying an additional 62,010 shares during the period. American Century Companies Inc.’s holdings in Health Catalyst were worth $6,654,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Health Catalyst by 12.0% during the third quarter. Vanguard Group Inc. now owns 5,941,658 shares of the company’s stock worth $57,634,000 after buying an additional 636,395 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Health Catalyst by 72.8% during the second quarter. Point72 Asset Management L.P. now owns 2,397,256 shares of the company’s stock worth $29,966,000 after buying an additional 1,010,356 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in Health Catalyst by 3.3% during the first quarter. Clearbridge Investments LLC now owns 2,317,997 shares of the company’s stock worth $60,569,000 after buying an additional 73,852 shares during the last quarter. State Street Corp lifted its holdings in shares of Health Catalyst by 1.6% during the 2nd quarter. State Street Corp now owns 1,418,763 shares of the company’s stock valued at $17,735,000 after purchasing an additional 22,860 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Health Catalyst by 55.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,204,624 shares of the company’s stock valued at $15,057,000 after purchasing an additional 428,942 shares in the last quarter. Institutional investors own 86.63% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on HCAT shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Tuesday, March 5th. Barclays started coverage on Health Catalyst in a report on Wednesday, January 3rd. They set an “overweight” rating and a $14.00 price objective on the stock. Canaccord Genuity Group cut their price objective on Health Catalyst from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, February 23rd. JPMorgan Chase & Co. upgraded Health Catalyst from a “neutral” rating to an “overweight” rating and cut their price objective for the company from $14.00 to $11.00 in a report on Wednesday, December 13th. Finally, Piper Sandler reiterated an “overweight” rating and set a $15.00 price objective (down previously from $17.00) on shares of Health Catalyst in a report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.50.

View Our Latest Research Report on Health Catalyst

Insiders Place Their Bets

In other Health Catalyst news, insider Linda Llewelyn sold 3,163 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $10.83, for a total transaction of $34,255.29. Following the transaction, the insider now owns 68,048 shares of the company’s stock, valued at approximately $736,959.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.70% of the company’s stock.

Health Catalyst Stock Up 0.3 %

Shares of Health Catalyst stock opened at $7.49 on Wednesday. The business’s 50 day simple moving average is $9.07 and its 200 day simple moving average is $8.89. Health Catalyst, Inc. has a 52-week low of $6.60 and a 52-week high of $14.37. The firm has a market cap of $438.64 million, a PE ratio of -3.57 and a beta of 1.30. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.42 and a current ratio of 4.42.

Health Catalyst (NASDAQ:HCATGet Free Report) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.06. The firm had revenue of $75.08 million for the quarter, compared to analyst estimates of $73.67 million. Health Catalyst had a negative return on equity of 12.19% and a negative net margin of 39.92%. On average, analysts predict that Health Catalyst, Inc. will post -0.47 earnings per share for the current fiscal year.

About Health Catalyst

(Free Report)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

Featured Stories

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCATFree Report).

Institutional Ownership by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.